Ligand Pharmaceuticals Incorporated Q4 FY2025 earnings call

2025 was a defining year for Ligand with exceptional financial performance. Full year adjusted EPS exceeded original 2025 guidance by over 30%. Royalty revenue grew 48% over prior year. Congratulated Palvella Therapeutics on positive phase 3 trial data. Executed special situations transaction in 2025. Accelerating business development efforts in 2026 with expanded team, deeper pipeline, stronger capital base. Launched more sophisticated portfolio management process to drive value across partnerships.

2025 full year core revenue was $240 million, up 43% year-over-year. Royalty revenue grew to $161 million, an increase of 48% year-over-year, driven primarily by Felspari, Merck's O2VeR, CapPaxi, and Record RD's Carzeba. Q4 2025 royalty revenue was $50.5 million, up 45% year-over-year. Felspari had U.S. net sales of $322 million for the full fiscal year. Merck's O2VeR had U.S. net sales of $506 million for 2025. Capvaxiv had full-year net sales of $755 million. Carziba had full-year net sales of 159 million euros.

2026 expected adjusted EPS of approximately $8 to $9 per share, royalty revenue of $200 to $225 million (32% growth at midpoint), CAPTASOL revenue of $35 to $40 million, contract revenue of $10 to $20 million, total revenue of $245 to $285 million. 2025-2030 royalty receipts expected 23% CAGR, driven by commercial programs (15% annual growth), development stage programs (5%), and future investments (at least 3%).

Actual events or results may differ materially from projections. Refer to Ligand's SEC filings for risks and uncertainties that could cause actual results to differ.

Q: Regarding clinical update expectations for late-stage royalty portfolio, A: Todd mentioned active late-stage pipeline with assets like CARZIVA, Bot-Bal, AVIM therapy, Virtue SAB trials, cutorium rapamycin for MLM and CVM, lasofoxetine, T-Zield.

Q: Update on monetizing older assets, A: Lauren said there are 5 to 10 opportunities, some new investment opportunities and some where can offer advice.

Q: T-Zield larger opportunity, A: Lauren explained T-Zield's indications and potential.

Q: Impact of FSGS approval delay on 2026 guidance, A: Todd said FSGS assumption in 2026 is $4 million, minor impact.

Q: Partnership selection criteria update, A: Todd said average deal size may increase as portfolio value grows.

Q: Filspari approval delay impact and market opportunities, A: Related人员 explained Filspari's market opportunities in IGAN and FSGS.

Q: Raleigh's status and Peltos equity, A: Related人员 said Raleigh is key royalty driver, Peltos equity is long-term view.

Q: Market impact on opportunities, A: Todd said royalty financing growing regardless of market, culling pipeline aggressively.